Autoimmune Aspects of Depigmentation in Vitiligo

Journal of Investigative Dermatology Symposium Proceedings

Volumn 9, Issue 1, 2004, Pages 68-72

  Le Poole, I Caroline ^a   Wañkowicz Kaliñska, Anna ^b   Van Den Wijngaard, René M J G J ^a   Nickoloff, Brian J ^a   Das, Pranab K ^c,d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Autoantibody; Complement; Melanocyte; Melanoma; T cell

Indexed keywords

HEAT SHOCK PROTEIN;

ANTIGEN EXPRESSION; AUTOIMMUNITY; CELL ACTIVATION; CELL INFILTRATION; CELL MIGRATION; CONFERENCE PAPER; CYTOTOXICITY; DENDRITIC CELL; DEPIGMENTATION; EPIDERMIS; HUMAN; MELANOCYTE; T LYMPHOCYTE; VITILIGO;

EID: 0347301886     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1087-0024.2004.00825.x     Document Type: Conference Paper

References (48)

1. Alkhateeb A, Stetler GL, Old W, et al: Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-P32.2. Hum Mol Genet 11:661-667, 2002
2. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK: Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12:1539-1546, 2002
3. Becker JC, Guldberg P, Zeuthen J, Brocker EB, Straten PT: Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 113:1033-1038, 2002
4. Boissy RE, Liu YY, Medrano EE, Nordlund JJ: Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 97:395-404, 1991
5. Buc M, Busova B, Hegyi E, Kolibasova K: Vitiligo is associated with HLA-A2 and HLA-Dw7 in the Slovak populations. Folia Biol 42:23-25, 1996
6. Burgaud JL, Poosti R, Fehrentz JA, Martinez J, Nahon JL: Melanin-concentrating hormone binding sites in human SVK14 keratinocytes. Biochem Biophys Res Commun 29:622-629, 1997
7. Gasp CB, She JX, McCormack WT: Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res 15:62-66, 2002
8. Das PK, van den Wijngaard RMJGJ, Wankowicz-Kalinska A, Le Poole IC: A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol 22:130-136, 2001
9. Engelhard VH, Bullock TN, Colla TA, Sheasley SL, Mullins DW: Antigens derived from melanocyte differentiation proteins, self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 188:136-146, 2002
10. Gilhar A, Zelickson B, Ulman Y, Etzioni A: In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 105:683-686, 1995
11. Harning R, Cui J, Bystryn JC: Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 97:1078-1080, 1991
12. Hegedus L, Heidenheim M, Gervil M, Hjalgrim H, Hoier-Madsen M: High-frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 74: 120-3, 1994
13. Le Poole IC, van den Wijngaard RMJGJ, Westerhof W, Dutrieux RP, Das PK: Presence or absence of melanocytes in vitiligo lesions: an immunhistochemical investigation. J Invest Dermatol 100:816-822, 1993
14. Janjic BM, Lu G, Pimenov A, Whiteside TL, Storkus WJ, Vujanovic NL: Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol 168:1823-1830, 2002
15. Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA: The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 21:237-246, 1998
16. Kemp EH, Waterman EA, Hawes BE, et al: The melanocortin receptor 1, a novel target of autoantibody responses in vitiligo 2002. J Clin Invest 109:923-930, 2002
17. Le Poole IC, Mutis T, van den Wijngaard RMJGJ, et al: A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 151:7284-7292, 1993
18. Le Poole IC, Riker AI, Quevedo ME, et. al: Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 160:521-528, 2002
19. Le Poole IC, Sarangarajan R, Zhaoy R, et al: 'VIT1', a novel gene associated with vitiligo. Pigment Cell Res 14:475-484, 2001
20. Le Poole IC, van den Wijngaard RMJGJ, Westerhof W, Das PK: Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 148:1219-1228, 1996
21. Lu G, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL: Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha (1) beta (2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 168:1931-1839, 2002
22. Maeda T, Hao C, Tron VA: Ultraviolet (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes. Cutan Med Surg 5:294-298, 2001
23. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273, 2000
24. Medrano EE, Nordlund JJ: Succussful culture of adult human melanocytes obtaines from normal and vitiligo donors. J Invest Dermatol 95:441-445, 1990
25. Naughton GK, Eisinger M, Bystryn JC: Antibodies to normal melanocytes in vitiligo. J Exp Med 158:246-251, 1983
26. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB: Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 9:689-696, 1983
27. Nordlund JJ, Majumder PP: Recent investigations on vitiligo vulgaris. Dermatol Clin 15:69-78, 1997
28. Norris DA, Horikawa T, Morelli JG: Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 7:193-203, 1994
29. Norris DA, Kissinger RM, Naughton GM, Bystryn JC: Evidence for immunologic mechanisms in human vitiligo. Patients' sera induce damage and antibody-dependent cytotoxicity. J Invest Dermatol 90:783-789, 1988
30. O'Malley MA, Mathias CG, Priddy M, Molina D, Grote AA, Halperin WE: Occupational vitiligo due to unsuspected presence of phenolic antioxidant byproducts in commercial bulk rubber. J Occup Med 30:512-516, 1988
31. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V: High frequency of skin-homing melanocytes cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Mecl 188:1203-1208, 1998
32. Ortonne JP, Mosher DB, Fitzpatrick TB: Vitiligo and Other Hypomelanoses of Hair and Skin. New York: Plenum, 1983; p. 1-55, 129-310
33. Overwijk WW, Lee DS, Surman DR, et al: Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice. Requirement for Cd4+ T Lymphocytes. Proc Natl Acad Sci USA 96:2982-2987, 1999
34. Overwijk WW, Restifo NP: Autoimmunity and the immunotherapy of cancer: Targeting the 'self' to destroy the 'other'. Crit Rev Immunol 20:433-450, 2000
35. Ramaiah A, Mojamdar MV, Amarnath VM: Vitiligo in the SSK community of Bangalore. Indian J Dermatol Lepr 54:251-254, 1988
36. Sakai C, Kawakami Y, Law LW, Furumura M, Hearing VJ.: Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 7:83-95, 1997
37. Schallreuter KU, Tobin DJ, Panske A: Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed Caucasian patients with vitiligo. Dermatology 204:194-201, 2002
38. Srivastava PK, Amato RJ: Heat shock proteins. The 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine 19:2590-2597, 2001
39. Treka J, Moroi Y, Clynes RA, et al: Redundant and alternative roles for activating the receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 16:861-868, 2002
40. Van Elzas A, Sutmuller RPM, Hurwitz AA, et al: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J Exp Med 194:481-489, 2001
41. Venneker GT, de Waal LP, Westerhof W, D'Amaro J, Schreuder GM, Ashgar SS: HLA associations in vitiligo patients in the Dutch population. Dis Markers 11:187-190, 1993
42. Venneker GT, Vodegel RM, Okada N, Westerhof W, Bos JD, Ashgar SS: Relative contributions of decay acceleration factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement. Immunobiology 198:476-484, 1998
43. Wang S, Bartido S, Yang G, et al: A role for a melansome transport signal in accessing the MHC class II presentation pathway and eliciting CD4+ T cell responses. J Immunol 163:5820-5826, 1999
44. van den Wijngaard RMJGJ, Ashgar S, Pijnenborg Y, Tigges B, Westerhof W, Das PK: Aberrant expression of complement regulatory proteins, membrane cofactor protein (MCP) and decay accelerating factor (DAF) in the involved epidermis of patients with vitiligo. Br J Dermatol 146:80-87, 2002a
45. van den Wijngaard RMJGJ, Aten J, Scheepmaker A, Le Poole IC, Tigges B, Westerhof W, Das PK: Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 143:573-581, 2002b
46. van den Wijngaard RMJGJ, Wankowicz-Kalinska A, Le Poole IC, Tigges B, Westerhof W, Das PK: Local immune response in skin of generalized vitiligo patients: Destruction of melanocytes is associated with the prominent presence of CLA + T cells at the perilesional site. Lab Invest 80:1299-1309, 2000
47. van den Wijngaard RMJGJ, Wankowicz-Kalinska A, Pals S, Weening J, Das PK: Autoimmune melanocyte destruction in vitiligo. Lab Invest 81:1061-1067, 2001
48. Yee C, Thompson JA, et al: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 192:1637-1643, 2000